Leading Precision Medicine in Asia

Dr. Tsai is the Founder and Chair of Scientific Advisory Board of PDC4PM. He is the Distinguished Investigator in Institute of Molecular and Genomic Medicine, NHRI. In 2017, he was the Principal Investigator of the Flagship Program of Precision Medicine for Asia Pacific Biomedical Silicon Valley, which successfully established TGIA Inc. under Public-Private Partnership structure. He is also the founder of  SP BioMed and a Professor of National Yang Ming Chiao Tung University.

Dr. Tsai received his Ph.D. in Human Genetics, Mt. Sinai School of Medicine, City University of NY (USA). 

Dr. Kirby is the Co-founder and Scientific & Legal Advisor of PDC4PM. He was the Senior Consultant of Flagship Program of Precision Medicine NHRI. He is the Director of TIGeR Biopharm PTE. LTD. and a 

Professor Emeritus of National Yang Ming Chiao Tung University.

Dr. Kirby received his M.A in Genetics from Cambridge University (UK), his Ph.D. in Genetics from the University of East Anglia (UK) and his Bachelor/Master of Laws (LLB/LLM) in Intellectual Property Law from the University of South Africa/Universiteit van Suid-Afrika.

Dr. Dunnenberger is the Co-founder and Scientific Advisory Board Member of PDC4PM. He is the Director of Pharmacogenomics at the NorthShore University Health System Center for Molecular Medicine and a member of the Clinical Pharmacogenetics Implementation Consortium (CPIC). He was the Senior Consultant of the Flagship Program of Precision Medicine for Asia Pacific Biomedical Silicon Valley.

Dr. Dunnenberger is a Pharm.D. from the University of Tennessee, (USA) and a Board-Certified Pharmacotherapy Specialist.